Amgen's Prognosis: Good, Not Assured

The biotech blue chip is seeing a payoff from its Immunex purchase. Is the new-drug pipeline big enough to keep profits healthy and growing?

By Amy Tsao

To continue reading this article you must be a Bloomberg Professional Service Subscriber.